278 related articles for article (PubMed ID: 35178030)
1. Future Directions in Diagnosis, Prognosis and Disease Monitoring of Adrenocortical Carcinoma: Novel Non-Invasive Biomarkers.
Cheng Y; Kou W; Zhu D; Yu X; Zhu Y
Front Endocrinol (Lausanne); 2021; 12():811293. PubMed ID: 35178030
[TBL] [Abstract][Full Text] [Related]
2. miRNAs orchestration of adrenocortical carcinoma - Particular emphasis on diagnosis, progression and drug resistance.
El-Dakroury WA; Midan HM; Abulsoud AI; Elshaer SS; El-Husseiny AA; Fathi D; Abdelmaksoud NM; Abdel Mageed SS; Elballal MS; Zaki MB; Abd-Elmawla MA; Al-Noshokaty TM; Rizk NI; Elrebehy MA; Hashem AH; Moustafa YM; Doghish AS
Pathol Res Pract; 2023 Aug; 248():154665. PubMed ID: 37418996
[TBL] [Abstract][Full Text] [Related]
3. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA
Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053
[TBL] [Abstract][Full Text] [Related]
4. The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.
Mizdrak M; Tičinović Kurir T; Božić J
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33578890
[TBL] [Abstract][Full Text] [Related]
5. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
6. Circulating Fascin 1 as a Promising Prognostic Marker in Adrenocortical Cancer.
Cantini G; Fei L; Canu L; De Filpo G; Ercolino T; Nesi G; Mannelli M; Luconi M
Front Endocrinol (Lausanne); 2021; 12():698862. PubMed ID: 34248854
[TBL] [Abstract][Full Text] [Related]
7. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
[TBL] [Abstract][Full Text] [Related]
8. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
9. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
[TBL] [Abstract][Full Text] [Related]
10. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
Puglisi S; Perotti P; Cosentini D; Roca E; Basile V; Berruti A; Terzolo M
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1125-1133. PubMed ID: 30117750
[TBL] [Abstract][Full Text] [Related]
11. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
12. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
13. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
Arlt W; Biehl M; Taylor AE; Hahner S; Libé R; Hughes BA; Schneider P; Smith DJ; Stiekema H; Krone N; Porfiri E; Opocher G; Bertherat J; Mantero F; Allolio B; Terzolo M; Nightingale P; Shackleton CH; Bertagna X; Fassnacht M; Stewart PM
J Clin Endocrinol Metab; 2011 Dec; 96(12):3775-84. PubMed ID: 21917861
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Adrenocortical Carcinoma.
Vaidya A; Nehs M; Kilbridge K
Surg Pathol Clin; 2019 Dec; 12(4):997-1006. PubMed ID: 31672303
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study.
Pinzani P; Scatena C; Salvianti F; Corsini E; Canu L; Poli G; Paglierani M; Piccini V; Pazzagli M; Nesi G; Mannelli M; Luconi M
J Clin Endocrinol Metab; 2013 Sep; 98(9):3731-8. PubMed ID: 23836937
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs in adrenal tumors.
Igaz P
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):155-159. PubMed ID: 30801265
[TBL] [Abstract][Full Text] [Related]
17. 5th International ACC Symposium: An Outlook to Current and Future Research on the Biology of Adrenocortical Carcinoma: Diagnostic and Therapeutic Applications.
Lalli E; Sasano H
Horm Cancer; 2016 Feb; 7(1):44-8. PubMed ID: 26666256
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease.
Libé R; Huillard O
Cancer Treat Res Commun; 2023; 37():100759. PubMed ID: 37690343
[TBL] [Abstract][Full Text] [Related]
19. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
20. Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.
Clay MR; Pinto EM; Fishbein L; Else T; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2022 Mar; 107(4):1159-1169. PubMed ID: 34850906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
